Latest Ratios: P/E Ratio -1.0x · EV/EBITDA N/A · ROE N/A. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $21M | $7M | $5M | $21M | $56M | $116M | $26M | $78M | $15M | $18M | $33M |
| Enterprise Value | $18M | $3M | $4M | $18M | $50M | $88M | $17M | $73M | $9M | $3M | $-81078 |
| P/E Ratio → | -1.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 727.63 | 163.52 | 2.38 | 38520.36 | 5565.00 | 7.64 | 26.15 | 49939.02 | 1139.91 | 2.00 | 8.20 |
| P/B Ratio | — | — | — | 1.77 | 3.05 | 3.07 | 1.83 | 5.51 | 0.78 | 0.69 | 0.98 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 69.50 | 1.94 | 32313.15 | 5013.00 | 5.83 | 17.28 | 46466.81 | 691.94 | 0.36 | -0.02 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -33850.0% | -33850.0% | -1233.2% | -4346661.1% | -253990.0% | -42.0% | -1234.3% | -535463.3% | -95262.4% | -123.5% | -313.7% |
| Net Profit Margin | -49290.5% | -49290.5% | -1160.2% | -3687419.8% | -250140.0% | -55.5% | -1261.7% | -656230.0% | -46071.1% | -121.4% | -296.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -2634.3% | -135.0% | -89.1% | -32.4% | -88.0% | -61.4% | -27.1% | -36.0% | -30.8% |
| ROA | -149.8% | -149.8% | -107.8% | -64.0% | -53.2% | -20.8% | -56.4% | -41.6% | -18.8% | -29.9% | -29.5% |
| ROIC | — | — | — | -169.4% | -165.5% | -61.2% | -129.5% | -56.8% | -77.2% | -143.0% | -4002.9% |
| ROCE | — | — | -349.1% | -97.1% | -64.4% | -18.8% | -66.0% | -38.7% | -45.6% | -33.6% | -32.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.15 | 0.10 | — | — | — | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | -0.29 | -0.30 | -0.73 | -0.62 | -0.38 | -0.31 | -0.57 | -0.99 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -12122.25 | — | — | -4.02 | — | — | — |
Net cash position: cash ($4M) exceeds total debt ($396000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.35 | 0.35 | 0.24 | 1.42 | 1.40 | 3.53 | 2.10 | 3.42 | 2.38 | 3.62 | 23.81 |
| Quick Ratio | 0.35 | 0.35 | 0.24 | 1.42 | 1.40 | 3.53 | 2.10 | 3.42 | 2.38 | 3.62 | 23.50 |
| Cash Ratio | 0.31 | 0.31 | 0.06 | 0.69 | 1.09 | 3.31 | 1.73 | 2.46 | 1.53 | 2.68 | 23.36 |
| Asset Turnover | — | 0.01 | 0.11 | 0.00 | 0.00 | 0.26 | 0.04 | 0.00 | 0.00 | 0.24 | 0.11 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 782.14 | 21.03 | 69054.05 | 1861.50 | — | 0.16 | 363270.79 | 31.47 | 0.21 | 8.16 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $1M | $479600 | $368600 | $265000 | $235400 | $152459 | $120007 | $100959 | $97634 | $89203 |
Imminent clinical funding shortfall
Based on reported figures, the company's P/S ratio of 794.65 appears detached from fundamental performance, as the lack of recurring revenue renders traditional valuation metrics largely irrelevant for assessing the firm's intrinsic value in the current clinical-stage biotech market environment.
The extreme P/S multiple suggests that investors are pricing the company purely on the binary potential of its pipeline rather than any underlying financial health. This valuation is highly sensitive to market sentiment regarding clinical trial outcomes, and any delay in data readouts may lead to a rapid compression of these multiples.
As reported in financial statements, the company's net margin of -504.9% in 2025Q4 highlights a profound lack of earning power, confirming that the business model is currently structured to consume capital rather than generate sustainable operating profits through its research activities.
The 100% gross margin is an accounting artifact of zero product sales, which masks the reality that the company has no commercial engine to offset its heavy R&D overhead. Investors should monitor the operating margin as a proxy for the efficiency of the clinical development program rather than as a measure of profitability.
According to recent SEC filings, the company's current ratio has deteriorated to 0.35, indicating that short-term assets are insufficient to cover immediate liabilities and suggesting that the firm faces a critical liquidity crunch that necessitates urgent external capital intervention.
The rapid decline in the quick ratio from 3.53 in 2021Q4 to 0.35 in 2025Q4 reflects a systematic erosion of the firm's ability to meet its obligations without further dilution. This liquidity profile leaves the company with virtually no margin for error regarding clinical trial timelines or unexpected operational costs.
Based on historical data, the most commonly misapplied ratio for this business model is the P/E ratio, which obscures the reality that the company is in a pre-revenue development phase where accounting losses are a function of investment rather than operational failure.
Using P/E or EBITDA to evaluate a firm with no commercial product is fundamentally flawed, as these metrics ignore the capital-intensive nature of drug development. Analysts should instead focus on the cash-to-burn ratio and the projected runway to the next clinical milestone to assess the firm's true financial viability.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KZIA stock.
Kazia Therapeutics Limited's current P/E ratio is -1.0x. The historical average is 2.1x.
Based on historical data, Kazia Therapeutics Limited is trading at a P/E of -1.0x. Compare with industry peers and growth rates for a complete picture.
Kazia Therapeutics Limited has 100.0% gross margin and -33850.0% operating margin.